What is the bioscience industry doing to address the ethical issues it faces?

PLoS Medicine

Volumn 3, Issue 5, 2006, Pages 600-601

  Novas, Carlos ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR; CLINICAL PRACTICE; DECISION MAKING; MEDICAL ETHICS; MEDICINE; METHODOLOGY; SHORT SURVEY; BIOTECHNOLOGY; DRUG INDUSTRY; ETHICS; HUMAN; LEADERSHIP; MANAGEMENT; NOTE; POLICY; PUBLIC RELATIONS;

BIOTECHNOLOGY; DRUG INDUSTRY; ETHICS, PROFESSIONAL; HUMANS; INTERPROFESSIONAL RELATIONS; LEADERSHIP; ORGANIZATIONAL POLICY; POLICY MAKING;

EID: 33744476124     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030142     Document Type: Short Survey

References (5)

1. Caplan A, Elliott C (2004) Is it ethical to use enhancement technologies to make us better than well? PLoS Med 1(3): e52. DOI: 10.1371/journal.pmed. 0010052
2. Mackie JE, Taylor AD, Finegold DL, Daar AS, Singer PA (2006) Lessons on ethical decision making from the bioscience industry. PLoS Med 3(5): e129. DOI: 10.1371/journal.pmed.0030129
3. Turner L (2004) Bioethic$ Inc. Nat Biotechnol 22: 947-948.
4. Elliott C (2001 September 24) Pharma buys a conscience. The American Prospect 12. Available: http://www.prospect.org/print/V12/17/elliott-c.html. Accessed 6 February 2006.
5. [Anonymous] (2005 July 7) Pharma owns bioethics (And other fables). The Editors Blog of the American Journal of Bioethics. Albany (New York). Available: http://blog.bioethics.net/2005/07/pharma-owns-bioethics-and-other-fables.html. Accessed 6 February 2006.